NASDAQ, CRTX - Cortexyme Inc
Critical Therapeutics, Inc. is a biopharmaceutical company focused on the
development and commercialization of products designed to treat respiratory,
inflammatory and critical care diseases linked to the body?s inflammatory
response. Our marketed product is ZYFLO CR, an extended-release formulation of
zileuton, which the U.S. Food and Drug Administration, or FDA, approved in May
2007 for the prevention and chronic treatment of asthma in adults and children
12 years of age or older. We licensed from Abbott Laboratories exclusive
worldwide rights to ZYFLO CR, ZYFLO, an immediate-release tablet formulation of
zileuton, and other formulations of zileuton for multiple diseases and
conditions. We began selling ZYFLO CR in the United States in September 2007. In
addition, we are developing an injectable formulation of zileuton, or zileuton
injection.
In preparation for commercialization of ZYFLO CR, we increased our sales force
from 18 to 42 representatives. ...
Read SEC Filing on NASDAQ.com »